Samira Laouirem

Samira Laouirem

Auto-generated profile, based on publicly available information

Samira Laouirem

Université Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, Paris, France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
JFJulie Le Faouder
Julie Le Faouder
SLSamira Laouirem
Samira Laouirem
MCManuel Chapelle
Manuel Chapelle
MAMiguel ALBUQUERQUE
Miguel ALBUQUERQUE
JBJacques Belghiti
Jacques Belghiti
PBPierre Bedossa
Pierre Bedossa

30 June 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
SLSamira Laouirem
Samira Laouirem
JFJulie Le Faouder
Julie Le Faouder
TATheodore Alexandrov
Theodore Alexandrov
DMDenis Mestivier
Denis Mestivier
TLThibaut LEGER
Thibaut LEGER
PBPierre Bedossa
Pierre Bedossa

9 December 2016 in Clinical Science
Verified
Journal Article
Closed access
PDF file
FCFrançois Cauchy
François Cauchy
MMMouniya Mebarki
Mouniya Mebarki
BLBenjamin Leporq
Benjamin Leporq
SLSamira Laouirem
Samira Laouirem
MAMiguel ALBUQUERQUE
Miguel ALBUQUERQUE
VPValérie Paradis
Valérie Paradis
Purpose Studies suggest that metformin, widely used for treating type 2 diabetes, possesses innate antineoplastic properties. For metabolic syndrome patients with hepatocellular carcinoma, metformin may provide antitumoral effects We evaluated the impact of metformin on tumor growth and visceral fat composition using relevant preclinical models of metabolic syndrome. Experimental Design Studies were performed in three hepatoma cell lines, in HepG2 xenograft mice fed with standard chow-diet (SC), 60% high-fat diet (HFD) or 30% fructose diet (FR), and an ex vivo model of human cultured hepatocellular carcinoma slices. Visceral fatty acid composition was analyzed by MRI. Results Metformin had a dose-dependent inhibitory effect on cell proliferation and apoptosis in vitro through the deregulation of mTOR/AMPK, AKT and ERK signaling pathways. Tumor engraftment rates were higher in HFD mice than SC mice (hepatic: 79% vs 25%, p=0.02) and FR mice (subcutaneous: 86% vs 50%, p=0.04). Subcutaneous tumor volume was increased in HFD mice (+64% vs FR and SC, p=0.03). Metformin significantly decreased subcutaneous tumor growth via cell cycle block and mTOR pathway inhibition, and also induced hypoxia and decreased angiogenesis. In ex vivo tumor slices, metformin treatment led to increased necrosis, decreased cyclin D1, and increased CA-9. Metformin caused qualitative changes in visceral fat composition of HFD mice, with decreased proportions of polyunsaturated fatty acids (14.6% ± 2.3% vs 17.9% ± 3.0%, p =0.04). Conclusions The potent antitumoral effects of metformin in multiple preclinical models implicating several molecular mechanisms provide strong rationale for clinical trials including combination studies in hepatocellular carcinoma patients.

1 March 2014 in Pancreatology
Verified
Journal Article
Closed access
VRVinciane Rebours
Vinciane Rebours
JFJulie Le Faouder
Julie Le Faouder
SLSamira Laouirem
Samira Laouirem
MMMounya Mebarki
Mounya Mebarki
MAMiguel ALBUQUERQUE
Miguel ALBUQUERQUE
ACAnne Couvelard
Anne Couvelard

12 February 2014 in Proteomics
Verified
Journal Article
Closed access
PDF file
JFJulie Le Faouder
Julie Le Faouder
SLSamira Laouirem
Samira Laouirem
TATheodore Alexandrov
Theodore Alexandrov
SBSoundes Ben‐Harzallah
Soundes Ben‐Harzallah
TLThibaut LEGER
Thibaut LEGER
VPValérie Paradis
Valérie Paradis